← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 CRISPR Therapeutics CRSP $4.98B	–	–	–	–
77	77 DELISTED CATALENT, INC. CTLT	–	–	–	–
78	CYAD 78 DELISTED Celyad Oncology SA American Depositary Shares CYAD	–	–	–	–
79	DBTX 79 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
80	80 DELISTED DermTech, Inc. Common Stock DMTK	–	–	–	–
81	81 Ginkgo Bioworks DNA $792M	–	–	–	–
82	82 Design Therapeutics DSGN $656M	–	–	–	–
83	83 Precision BioSciences DTIL $170M	–	–	–	–
84	84 Editas Medicine EDIT $375M	–	–	–	–
85	85 enGene Therapeutics ENGN $115M	–	–	–	–
86	86 Enlivex Ltd ENLV $4.46M	–	–	–	–
87	87 Estrella Immunopharma ESLA $23.3M	–	–	–	–
88	88 Fate Therapeutics FATE $231M	–	–	–	–
89	89 FibroBiologics FBLG $7.08M	–	–	–	–
90	90 4D Molecular Therapeutics FDMT $711M	–	–	–	–
91	91 Fulgent Genetics FLGT $587M	–	–	–	–
92	FRLN 92 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
93	93 DELISTED Generation Bio GBIO	–	–	–	–
94	94 CytoMed Therapeutics GDTC $10.4M	–	–	–	–
95	95 Guardant Health GH $22.3B	–	–	–	–
96	GMDA 96 DELISTED Gamida Cell Ltd. Ordinary Shares GMDA	–	–	–	–
97	97 Corgi Genomics & Precision Medicine ETF GNMX $1.68M	–	–	–	–
98	98 Global X Genomics & Biotechnology ETF GNOM $99.5M	–	–	–	–
99	99 Genprex GNPX $1.88M	–	–	–	–
100	100 Genenta Science GNTA $32.3M	–	–	–	–